Les Ulis, France

Nicolas S George

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2020-2022.

USPTO Granted Patents = 3 

% Patents Active = 100.0


 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Nicolas S. George

Introduction

Nicolas S. George is a notable inventor based in Les Ulis, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of 3 patents to his name, his work continues to impact the industry.

Latest Patents

One of his latest patents includes the development of heterocyclic amides as kinase inhibitors. This patent discloses compounds that have the potential to be used in various therapeutic applications. The innovative nature of his work showcases his commitment to advancing medical science.

Career Highlights

Nicolas S. George is currently employed at GlaxoSmithKline Intellectual Property Development Limited. His role at this prominent company allows him to further his research and development efforts in the pharmaceutical sector. His expertise in the field has positioned him as a valuable asset to his team.

Collaborations

Some of his notable coworkers include Niall Andrew Anderson and Deepak Bandyopadhyay. Their collaborative efforts contribute to the innovative projects at GlaxoSmithKline, enhancing the potential for groundbreaking discoveries.

Conclusion

Nicolas S. George's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…